Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $14.3333.

Several research analysts have commented on the company. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research note on Wednesday, June 24th. Leerink Partners began coverage on shares of Altimmune in a research note on Monday, June 22nd. They set an “outperform” rating and a $10.00 target price on the stock. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. Finally, Citizens Jmp cut their price objective on Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. lifted its holdings in shares of Altimmune by 27.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after purchasing an additional 1,928 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock worth $247,000 after purchasing an additional 2,241 shares during the last quarter. Concurrent Investment Advisors LLC lifted its holdings in Altimmune by 10.4% during the 4th quarter. Concurrent Investment Advisors LLC now owns 26,508 shares of the company’s stock worth $96,000 after buying an additional 2,500 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Altimmune by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,945 shares of the company’s stock valued at $108,000 after buying an additional 2,748 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Altimmune by 4.0% in the fourth quarter. Deutsche Bank AG now owns 79,940 shares of the company’s stock valued at $289,000 after buying an additional 3,047 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Trading Up 5.9%

Shares of ALT stock opened at $3.42 on Monday. Altimmune has a fifty-two week low of $2.56 and a fifty-two week high of $6.44. The stock’s fifty day moving average price is $3.03 and its two-hundred day moving average price is $3.19. The company has a debt-to-equity ratio of 0.07, a quick ratio of 26.78 and a current ratio of 26.78. The company has a market cap of $665.26 million, a PE ratio of -4.38 and a beta of 0.18.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. Altimmune had a negative return on equity of 31.41% and a negative net margin of 214,860.98%. Equities analysts predict that Altimmune will post -0.58 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.